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Abstract
Acute interstitial nephritis (AIN) represents a significant
cause of acute renal failure in hospital practice. An increas-
ing number of drugs are known to cause AIN. Due to the
lack of prospective, randomized clinical trials, the most ef-
fective management is still uncertain, especially the role of
steroids in the resolution of interstitial nephritis remains to
be further defined. We report on a case with pantoprazole-
induced interstitial nephritis and on the effect of steroids
during ongoing drug exposure. In spite of ongoing drug
exposure, steroids led to almost complete resolution of
the inflammatory infiltrates. Early diagnosis of interstitial
nephritis by renal biopsy and identification of the causative
drug and its withdrawal remains the mainstay of treatment.
However, the additional use of steroids has the potential to
eradicate inflammatory infiltrates more rapidly and com-
pletely and may thus be important to minimize subsequent
chronic damage.
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Introduction
Since the first description of acute interstitial nephritis
(AIN) by Councilman in 1898 as a post-infectious acute
inflammatory renal disease associated with diphtheria
and scarlet fever, an increasing number of causative agents
have been identified [1]. The prevalence of AIN ranges
from 2–5%, depending on the biopsy series. Among biop-
sies taken for the diagnosis of acute renal failure, AIN ac-
counts for from 3–15% [2] up to even 27% of cases [3].
Thus, AIN represents a significant cause of acute renal
failure seen in hospital practice. The aetiologies are di-
verse, ranging from infection, drug therapy to systemic
disorders, although the most common cause of AIN are,
with increasing frequency [4], drugs. Traditionally, several
antibiotics are associated with a high prevalence of AIN.
During the last decade, potent gastric acid inhibitors, the
proton pump inhibitors (PPIs), are emerging as one of the
most common causes of drug-induced AIN [5,6]. Due to
the lack of prospective, randomized clinical trials, the most
effective management is still uncertain. Withdrawal of the
causative drug and treatment of the underlying infection
and disorder has been the mainstay of treatment. Several
retrospective studies and a number of case series reported
that steroids lead to a more rapid and more complete recov-
ery of renal function [7,8]. However, the additional role of
steroids to counteract the effects of the offending drug in
the resolution of AIN remains to be further defined. We re-
port on a case with pantoprazole-induced interstitial nephri-
tis. The benefit of steroids despite ongoing drug exposure is
demonstrated in serial renal biopsies.
Case report
A 35-year-old male was referred to our outpatient clinic for
the evaluation of mild renal insufficiency (K/DOQI stage II;
serum creatinine of 115 µmol/L (1.3 mg/dL); estimated glo-
merular filtration rate (eGFR), according to the MDRD
equation, of 75 mL/min/1.73 m2) [9]. Three years before,
he had undergone liver transplantation as a consequence
of multi-organ failure with fulminant hepatic failure. The
aetiology of the multi-organ failure was unclear. Acute re-
nal failure caused by biopsy-proven acute tubular necrosis
required temporary haemodialysis (Figure 1). Kidney func-
tion recovered well and serum creatinine was 80 µmol/L
(0.9 mg/dL) at discharge. At this time, the medication con-
sisted of tacrolimus (4 mg b.i.d.), mycophenolate mofetil
(1000 mg b.i.d.), prednisone (15 mg q.d.) and pantoprazole
(40 mg q.d.).
During the next 2.5 years, his creatinine level rose and
lay between 97 and 150 µmol/L (1.1 to 1.7 mg/dL; eGFR
between 60 and 90 ml/min/1.73 m2) [9]. During this time,
the patient suffered twice from gastroenteritis, accompa-
nied by a transient increase of the serum creatinine to
230 µmol/L (2.6 mg/dL) and 256 µmol/L (2.9 mg/dL), re-
spectively (Figure 1). Calcineurin inhibitor (CNI) toxicity
was assumed to be the most likely cause of the underlying
chronic kidney disease. However, to rule out other pathol-
ogies, a kidney biopsy was performed. At this time, the pa-
tient was well and the physical examination was
unremarkable. His body mass index was 32 kg/m2. Blood
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pressure was 118/72 mmHg and pulse 80/min. The creati-
nine level was 117 µmol/L (1.3 mg/dL) and the blood urea
nitrogen level 10.3 mmol/L (29 mg/dL). The white blood
cell count was 10.490 × 109/L and the eosinophil count
0.820 × 109/L (in all measurements before and after biopsy,
the eosinophil count was in the range and varied between
0.070 and 0.354 × 109/L). The haemoglobin level was 122
g/L (12.2 g/dL). The remaining laboratory values were
within the normal range. Trough level of tacrolimus was
6.8 µg/L (target range 4–6 µg/L). Urinary sediment exam-
ination revealed zero to three red blood cells and zero to
one white blood cell per high-power field; no casts were
present. In spot urine, neither glomerular nor tubular pro-
teinuria was found (albumin/creatinine ratio 0.35 mg/mmol
(<2.26), α1-microglobulin/creatinine ratio 0.82 mg/mmol
(<1.58)). Ultrasound examination demonstrated normal-
sized kidneys without abnormalities. His medication in-
cluded tacrolimus (2 mg in the morning and 3 mg in the
evening), mycophenolate mofetil (500 mg b.i.d.) and pan-
toprazole (20 mg q.d.). Prednisone had been stopped
14 months before. During the acute illness 3 years earlier,
pantoprazole had been given as ulcer prophylaxis and was
continued because of unspecific abdominal discomfort.
The ingestion of other drugs was convincingly denied, es-
pecially no NSAID was taken either orally or locally as
ointment.
By light microscopy, the biopsy contained 20 glomeruli,
which were unchanged by light, electron and immunoflu-
orescent microscopy. The same held true for the arterioles
and arteries, especially no CNI-associated lesions were
present. The main lesion was found in the tubulointerstitial
space: 25% showed a patchy fibrosis and tubular atrophy.
Inside and outside the fibrotic areas, dense infiltrates of
lymphocytes and histiocytes with a few IgM-positive plas-
ma cells and rarely eosinophils were present. Tubulitis of
non-atrophic tubules was very rare, and only very few lym-
phocytes were found within the tubules. Interestingly, a
few foamy macrophages (CD68-positive cells) were seen
in the interstitial space. Granulomas were absent. Viral in-
fection (cytomegalovirus, adenovirus and polyomavirus)
were excluded by special stains (Figure 2a, c, d).
The patient was treated by prednisone (0.75 mg/kg body
weight/day) (Figure 1). Mycophenolate mofetil was stopped
to avoid over-immunosuppression. Since the responsible
physicians were not aware that pantoprazole could be the
cause of interstitial nephritis, the dose of pantoprazole
was further increased to 40 mg to avoid gastric side effects
of steroids. Under steroid treatment, renal function re-
mained stable. Two months after steroid therapy, a second
kidney biopsy was performed to disclose the effect of ster-
oids. Light microscopy showed a near complete eradication
of inflammatory infiltrates, even in fibrotic areas, which
were otherwise unchanged as expected. Interstitial foam
cells were no longer present (Figure 2b). We identified pan-
toprazole as the probable causative agent for the chronic in-
terstitial nephritis and withdrew it. Prednisone was
continued at a reduced dose of 20mg daily (Figure 1). Three
months later, a third kidney biopsy was performed to dem-
onstrate the further morphological evolution after steroid re-
duction and withdrawal of the offending drug. Light
microscopy showed basically the same findings as the sec-
ond biopsy: moderate to severe interstitial fibrosis and tubu-
lar atrophy without remarkable inflammatory infiltrates.
During the following weeks, prednisone was tapered off
and stopped thereafter. The patient was instructed to avoid
any PPI in the future.
Fig. 1. Course of renal function, immunosuppressive therapy and PPI therapy after liver transplantation (Bx, biopsy; Tx, transplantation; HD,
haemodialysis); conversion factor for serum creatinine in micromoles per litre to milligrammes per decilitre: divide by 88.4.
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Discussion
In cases of biopsy-proven as well as clinically suspected
AIN, the mainstay of management has been withdrawal of
the potential aetiologic agent. During recent decades, ste-
roid therapy was reported to be helpful in shortening the re-
covery time and avoiding irreversible tubulointerstitial
changes [7,8]. However, there are still controversies about
the corticosteroid therapy. A retrospective study of renal bi-
opsy series could not demonstrate the beneficial effect of
corticosteroids [10]. We report here on an informative case
that documents the effectiveness of steroids in the resolution
of interstitial nephritis, despite ongoing treatment with the
probable ‘culprit’ even in an increased dose. This argues for
an important role of steroids in the therapy of AIN, even in
cases of chronic, long-lasting inflammation, as in our case.
Mycophenolate mofetil has also been reported to be effec-
tive in the treatment of interstitial nephritis [11]. However,
in our patient, interstitial nephritis developed under myco-
phenolate mofetil treatment but resolved under steroids.
The history of a 3-year treatment of pantoprazole and
the fact that morphological signs of chronicity, such as in-
terstitial fibrosis and tubular atrophy, were present let us
assume that the interstitial nephritis had already developed
months earlier. It is not surprising that steroids had no im-
pact on the established interstitial fibrosis and tubular atro-
Fig. 2. Morphological findings in the first and second renal biopsy: (a) first biopsy showing areas of tubular atrophy and interstitial fibrosis with
mononuclear infiltrates in fibrotic and non-fibrotic areas (the other compartments of the kidney are unchanged); (b) the interstitial infiltrates are
eradicated in the second biopsy (interstitial fibrosis and tubular atrophy are unchanged); (c and d) high-power magnification of the first biopsy
with prominent interstitial infiltrates, tubulitis in atrophic and rarely non-atrophic tubules and a few foam cells identified as macrophages by CD68
immunohistochemistry stain (d); a–c, periodic acid-Schiff stain; a and b, magnification ×100; c, ×400; d, ×600.
1718 M.J. Kim et al.
phy [7]. Therefore, to avoid chronic damage, the most im-
portant course of intervention remains the early withdraw-
al of the putative causative agent.
In cases of renal insufficiency, interstitial nephritis
should always be included in the differential diagnosis
and all drugs should be regarded as potential causative
agents. PPIs are one of the most commonly prescribed
drugs in the western world. Several side effects have been
reported including headache, diarrhoea, skin rashes, nau-
sea and constipation as mild and toxic hepatitis and severe
ophthalmopathies as severe side effects [12]. Although the
renal complications are rare, hyponatraemia and AIN have
been reported as direct adverse renal effects so far [13].
Case reports, retrospective studies and meta-analyses
during the last two decades strongly support the relationship
between PPI therapy and development of interstitial nephri-
tis [14–17]. The pathogenesis of PPI-induced interstitial ne-
phritis, as with most drug-induced interstitial nephritides, is
unclear; however, an immune reaction must be considered
[18].
Clinical presentation of PPI-induced interstitial nephritis
appears to be non-specific. The most common symptoms
quoted in a systematic review were nausea and emesis in
18 cases (30%) and malaise in 14 (23%); six cases (10%)
were asymptomatic [16]. The laboratory features were also
non-specific: haematuria (61%), proteinuria (56%), pyuria
(72%), all three findings (39%), eosinophilia (39%), eosi-
nophils in the urine (17%), anaemia (39%) and elevated
erythrocyte sedimentation rate (29%). The degree of azo-
taemia was highly variable, with creatinine ranging from
190 µmol/L (2.1 mg/dL) to 1193 µmol/L (13.5 mg/dL)
[14]. In our patient, the clinical presentation was unre-
markable. This underlines the importance of early renal bi-
opsy in the diagnosis of interstitial nephritis.
In conclusion, our case, documented by biopsies, shows
that corticosteroids are effective in the treatment of drug-
induced interstitial nephritis despite ongoing exposure to
the causative agent. Early diagnosis of interstitial nephritis
by renal biopsy and identification of the causative drug
and its withdrawal are essential in the treatment of intersti-
tial nephritis to avoid irreversible renal damage. The addi-
tional use of steroids helps to eradicate inflammatory
infiltrates rapidly and may thus be important to minimize
chronic damage.
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